We are live on ! Find out more
LP

LMR Partners Portfolio holdings

AUM $45.4B
1-Year Est. Return 60.68%
This Fund
S&P 500
This Quarter Est. Return
+23.27%
1 Year Est. Return
+60.68%
3 Year Est. Return
+183.94%
5 Year Est. Return
+215.13%
10 Year Est. Return
+663.15%
AUM
$11.9B
AUM Growth
-$665M
Cap. Flow
-$2.07B
Cap. Flow %
-17.42%
Top 10 Hldgs %
29.25%
Holding
1,790
New
534
Increased
200
Reduced
243
Closed
613

Top Sells

Rank Stock Value
1
TSM icon
TSMC
TSM
+$107M
2
GSK icon
GSK
GSK
+$58.9M
3
AVGO icon
Broadcom
AVGO
+$54M
4
UL icon
Unilever
UL
+$54M
5
MRVL icon
Marvell Technology
MRVL
+$48.3M

Sector Composition

Rank Sector Weight
1 Technology 11.5%
2 Communication Services 3.61%
3 Financials 3.6%
4 Healthcare 3.01%
5 Consumer Discretionary 1.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ANRO icon
901
Alto Neuroscience
ANRO
$1.08B
$219K ﹤0.01%
+51,700
New +$323K
TCRX icon
902
TScan Therapeutics
TCRX
$50.2M
$218K ﹤0.01%
71,800
AMBA icon
903
Ambarella
AMBA
$2.99B
$218K ﹤0.01%
+3,000
New +$191K
AVXL icon
904
CALL
Anavex Life Sciences
AVXL
$232M
$215K ﹤0.01%
+20,000
New +$154K
SANA icon
905
PUT
Sana Biotechnology
SANA
$913M
$212K ﹤0.01%
130,000
-220,000
-63% -$656K
EDU icon
906
New Oriental
EDU
$7.94B
$211K ﹤0.01%
+3,293
New +$211K
DD icon
907
DuPont de Nemours
DD
$18.9B
$209K ﹤0.01%
2,185
+134
+7% +$13.9K
VKTX icon
908
Viking Therapeutics
VKTX
$4.05B
$201K ﹤0.01%
+5,000
New +$285K
PCG icon
909
CALL
PG&E
PCG
$38.8B
$200K ﹤0.01%
9,900
-56,200
-85% -$1.14M
EWW icon
910
iShares MSCI Mexico ETF
EWW
$1.91B
$198K ﹤0.01%
+4,219
New +$218K
BARK.WS
911
DELISTED
BARK Inc Warrants
BARK.WS
$196K ﹤0.01%
+2,396,323
New +$212K
ML.WS
912
DELISTED
MoneyLion Inc. Warrants, each whole warrant exercisable 1/30th of a share of Class A common stock at an exercise price of $345.00 per whole share
ML.WS
$192K ﹤0.01%
+1,052,331
New +$110K
KMI icon
913
Kinder Morgan
KMI
$70.6B
$192K ﹤0.01%
7,020
-7,515
-52% -$196K
CCCC icon
914
C4 Therapeutics
CCCC
$397M
$184K ﹤0.01%
51,000
JOBY icon
915
Joby Aviation
JOBY
$7.25B
$182K ﹤0.01%
+22,396
New +$149K
ITOS
916
DELISTED
iTeos Therapeutics
ITOS
$176K ﹤0.01%
22,972
MET icon
917
MetLife
MET
$61.2B
$172K ﹤0.01%
+2,101
New +$175K
TAN icon
918
CALL
Invesco Solar ETF
TAN
$1.48B
$166K ﹤0.01%
+5,000
New +$184K
TAN icon
919
PUT
Invesco Solar ETF
TAN
$1.48B
$166K ﹤0.01%
+5,000
New +$184K
BTMWW
920
DELISTED
Bitcoin Depot Inc Warrant
BTMWW
$165K ﹤0.01%
+2,501,266
New +$162K
DAVEW icon
921
Dave Inc Warrants
DAVEW
$34.3M
$158K ﹤0.01%
+984,435
New +$111K
AEVAW
922
DELISTED
Aeva Technologies Warrants
AEVAW
$152K ﹤0.01%
+2,379,341
New +$131K
MTZ icon
923
MasTec
MTZ
$26.6B
$152K ﹤0.01%
1,115
-2,232
-67% -$299K
ANVS icon
924
PUT
Annovis Bio
ANVS
$71M
$149K ﹤0.01%
29,700
-242,900
-89% -$1.76M
BKSY.WS icon
925
BlackSky Technology Inc Warrants
BKSY.WS
$784K
$148K ﹤0.01%
+1,353,603
New +$84.9K

Similar funds

LMR Partners's Q4 2024 Portfolio in Review

As of Q4 2024, LMR Partners held 1,790 positions worth $11.9B, down 5.3% from $12.6B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

LMR Partners withdrew a net $2.07B in Q4 2024, closing 613 positions and reducing 243 holdings. Its most notable exit was Unilever, an estimated $54M position sold in full.

By sector, the portfolio is most concentrated in Technology at 12% of assets, up from 10% a quarter earlier, followed by Communication Services and Financials.

Against the trend, LMR Partners opened a new position in Vertex Pharmaceuticals worth $37.8M.

  • LMR Partners's largest Q4 2024 buy was Vertex Pharmaceuticals: 93,801 shares worth $37.8M.
  • LMR Partners added most to State Street SPDR S&P 500 ETF Trust in Q4 2024, an estimated $472M increase.
  • LMR Partners's biggest Q4 2024 reduction was TSMC, cutting an estimated $107M.
  • LMR Partners fully exited Unilever in Q4 2024, selling an estimated $54M.
  • LMR Partners's ten largest holdings make up 29% of its $11.9B portfolio in Q4 2024.
  • LMR Partners opened 534 new positions and closed 613 in Q4 2024.
  • LMR Partners's portfolio value fell 5.3% quarter-over-quarter to $11.9B.

Based on LMR Partners's 13F filing for Q4 2024, filed 14 Feb 2025.